0.3603
Precedente Chiudi:
$0.3488
Aprire:
$0.34
Volume 24 ore:
212.09K
Relative Volume:
1.13
Capitalizzazione di mercato:
$22.98M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.3079
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
+20.75%
1M Prestazione:
+8.53%
6M Prestazione:
-27.79%
1 anno Prestazione:
-70.11%
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PASG
Passage Bio Inc
|
0.3697 | 18.48M | 0 | -68.80M | -59.06M | -1.17 |
![]()
ONC
Beigene Ltd Adr
|
241.49 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
436.01 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.92 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
74.88 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-29 | Ripresa | Wedbush | Outperform |
2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
2022-01-19 | Downgrade | Goldman | Buy → Neutral |
2021-07-01 | Iniziato | Raymond James | Outperform |
2021-06-15 | Iniziato | BTIG Research | Buy |
2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
2021-02-04 | Iniziato | Guggenheim | Buy |
2021-01-25 | Iniziato | Wedbush | Outperform |
2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-12-11 | Iniziato | Citigroup | Neutral |
2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
2020-06-25 | Downgrade | Goldman | Buy → Neutral |
2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
2020-03-24 | Iniziato | Cowen | Outperform |
2020-03-24 | Iniziato | Goldman | Buy |
2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG Stock News - GuruFocus
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN
Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World
Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
Passage Bio Reports Q1 2025 Financial Results - TipRanks
Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com
Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com
Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times
Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Passage Bio (NASDAQ:PASG) vs. Agenus (NASDAQ:AGEN) Critical Contrast - The AM Reporter
Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World
PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):